Assessing the safety of sitagliptin in elderly participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)

MA Bethel, SS Engel, JB Green, Z Huang, KD Kaufman, E Standl, S Suryawanshi, F Van de Werf, ED Peterson and RR Holman

1Diabetes Trial Unit, University of Oxford, Oxford, UK, 2Merck Research Laboratories, Merck and Co. Inc., Kenilworth, USA, 3Duke Clinical Research Institute, Duke University School of Medicine, Durham, USA, 4Munich Diabetes Research Group e.V., Helmholtz Centre, Neuherberg, Germany, 5Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium

Aims: TECOS was a randomised, double-blind, placebo-controlled trial assessing the impact of sitagliptin added to usual care on cardiovascular (CV) outcomes. We examined sitagliptin’s safety profile in elderly (age ≥75 years) TECOS patients.

Methods: Safety assessments of sitagliptin vs placebo were performed for key CV endpoints and pre specified safety endpoints in the intention-to-treat population. Exposure-adjusted event rates for CV endpoints with 95% confidence interval (CI) for the difference between rates (sitagliptin minus placebo) were calculated. Treatment-emergent adverse events (AEs) were assessed in the all-patients-as-treated population.

Results: There were 2,004 elderly patients (68% male, mean age 78.3 years, mean diabetes duration 14.7 years) followed for a mean of 2.9 years (SD 1.0). The composite CV outcome rate (CV death, myocardial infarction or stroke) was higher in the elderly than the non-elderly population (6.0 vs 3.2 per 100 patient-years, difference 2.8, 95% CI 2.1–3.5), but there were no differences between treatment groups. Rates of heart failure requiring hospitalisation were higher in the elderly cohort (1.7 vs 1.0 per 100 patient-years, difference 0.7, 95% CI 0.4–1.1) but did not differ between treatment groups. In elderly patients, rates of malignancies (6.2% in both groups), bone fractures (4.5% sitagliptin vs 3.9% placebo) and hypoglycaemia (3.0% in both groups) were similar between treatment groups. Pancreatitis events were uncommon (sitagliptin 4, placebo 2). Incidences of treatment-emergent AEs and of diabetes-related complications were similar.

Conclusions: Sitagliptin was generally safe and well tolerated in elderly TECOS patients.